Rafael Holdings reports Phase 3 topline: prespecified subgroup meets significance; NDA on track

Rafael Holdings announced Phase 3 topline results for Trappsol Cyclo showing a non-significant primary result but a significant benefit in patients on background miglustat/leucine.Key Highlights:Original SEC Filing: Rafael Holdings, Inc. [ RFL ] - 8-K - Sep. 30, 2026This is an AI-powered summary. I…